Robert Bissonnette News Today

Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.

Researchers found that the percentage of patients with a PASI 75 response was higher among those receiving JNJ-77242113 vs placebo.

During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.

In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis.

Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide.

These new data highlight the efficacy of JNJ-77242113 as a potential oral therapy option for moderate-to-severe psoriasis patients.

At least 75% improvement in up to 79% of patients at 16 weeks, 90% improvement in 60%

The small-molecule oral investigational agent JNJ-77242113 at the highest dose tested was associated with reductions in psoriasis severity comparable to injectable biologic agents.

/PRNewswire/ -- Johnson & Johnson today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial results for...

MADISON, N.J.--(BUSINESS WIRE)--Jan 12, 2024--